Last reviewed · How we verify
AGN-190584
AGN-190584 is a Small molecule drug developed by Allergan. It is currently FDA-approved. Also known as: Pilocarpine hydrochloride, 1.25%.
At a glance
| Generic name | AGN-190584 |
|---|---|
| Also known as | Pilocarpine hydrochloride, 1.25% |
| Sponsor | Allergan |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age (PHASE3)
- Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses (PHASE4)
- A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (PHASE3)
- Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia (PHASE2)
- A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (PHASE3)
- Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (PHASE3)
- A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
- A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-190584 CI brief — competitive landscape report
- AGN-190584 updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about AGN-190584
What is AGN-190584?
AGN-190584 is a Small molecule drug developed by Allergan.
Who makes AGN-190584?
AGN-190584 is developed and marketed by Allergan (see full Allergan pipeline at /company/allergan).
Is AGN-190584 also known as anything else?
AGN-190584 is also known as Pilocarpine hydrochloride, 1.25%.
What development phase is AGN-190584 in?
AGN-190584 is FDA-approved (marketed).
Related
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Pilocarpine hydrochloride, 1.25%
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing